- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03524040
Imaging of Pilosebaceous Units and Acne Lesions by RCM and OCT Confocal Microscopy and Optical Coherence Tomography
May 11, 2018 updated by: Merete Haedersdal
Imaging of Pilosebaceous Units and Acne Lesions by Reflectance Confocal Microscopy and Optical Coherence Tomography
The purpose of the study was to investigate if reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) could be used in combination to investigate the morphology of pilosebaceous units and acne lesions in healthy subjects and in acne patients.Furthermore, to investigate contrast effects, biodistribution and selective photothermolysis provided by gold microparticles and diode laser pulses, using RCM, OCT and histology.
Study Overview
Study Type
Interventional
Enrollment (Actual)
21
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Copenhagen NV, Denmark, 2400
- Bispebjerg Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
All subjects
- Healthy men and women
- 18-45 years of age at baseline
- Legally competent, able to give verbal and written consent
- Communicate in Danish verbally as well as in writing
- Women with negative pregnancy-test
- Subject in good general health, is willing to participate and able to give informed consent, and can comply with protocol requirements.
- Fitzpatrick skin phototype I-III
Acne skin
- Subject with previous or prior clinical diagnosis of acne vulgaris, IGA score 1-4
- Subjects with 1 - 75 inflammatory facial lesions on the cheek, forehead, and/or chin, with no more than 2 nodulocystic lesions (see Appendix II, table 4)
- Each included patient with acne should represent at least 3 of 5 acne lesions
- Subject with in good general health, willing to participate and able to give informed consent, and able to comply with protocol requirements
Exclusion Criteria:
- Pregnant and lactating women
- Subject with a known allergy to gold, or any other ingredient in the microparticle suspension
- Individuals with skin diseases or skin lesions in the area of research interest will be excluded
- Subject with tattoo in the treatment area which may interfere with or confound evaluation of the study
- Subjects with severe acne (IGA 5) with imminent scarring potential, in the opinion of the investigator
- Subject with a history of keloids which is deemed clinically relevant in the opinion of the investigator
- Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or very severe acne requiring the continuation of systemic treatment during the study period.
- Subject with active skin disease or excessive scarring that, in the opinion of the investigator, would impact the ability to administer the gold microparticles or use of OCT/RCM in the areas
- Subject having used oral retionoid therapy such as isotretionoin within 3 months prior to baseline.
- Subject having used topical retinoids, topical corticosteroids, topical antibiotics or combination therapy within 2 weeks of baseline
- Subject having used over-the-counter topical products containing azelaic acid, benzoyl peroxide, and/or salicylic acid within 1 week of baseline
- Subject having used light treatments including Intense Pulsed Light or other lasers, microdermabrasion or chemical peels in the treatment area within 3 weeks of baseline.
- Subject who has received an investigational drug or was treated with an investigational device within 30 days prior to baseline.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Acne patients
Application of gold microparticles to 2-3 facial areas
|
Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
|
|
EXPERIMENTAL: Heatlhy volunteers
Application of gold microparticles to 2 facial areas
|
Gold microparticles (SEB-250) are massaged into 2 or 3 2x2 cm facial areas and exposed to 2 pulses from a diode laser
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acne morphology
Time Frame: 1 year
|
Qualitative assessment of acne lesions, pilosebaceous units and surrounding skin in RCM and OCT images
|
1 year
|
|
Gold microparticle biodistribution
Time Frame: 2 years
|
Evaluation of gold microparticle biodistribution and contrast effects in RCM and OCT images
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 1, 2016
Primary Completion (ACTUAL)
December 1, 2017
Study Completion (ACTUAL)
January 1, 2018
Study Registration Dates
First Submitted
May 1, 2018
First Submitted That Met QC Criteria
May 11, 2018
First Posted (ACTUAL)
May 14, 2018
Study Record Updates
Last Update Posted (ACTUAL)
May 14, 2018
Last Update Submitted That Met QC Criteria
May 11, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-16042830
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acne Vulgaris
-
Ghurki Trust and Teaching HospitalCompletedAcne Vulgaris | Acne Vulgaris on the FacePakistan
-
Galderma R&DCompletedSevere Acne VulgarisUnited States, Canada, Puerto Rico
-
Sebacia, Inc.CompletedInflammatory Acne VulgarisUnited States
-
Nexgen Dermatologics, Inc.Unknown
-
Rejuva Medical AestheticsHealMD, LLCNot yet recruitingAcne Vulgaris (Disorder)United States
-
InMode MD Ltd.RecruitingInflammatory Acne VulgarisUnited States
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingModerate to Severe Acne VulgarisChina
-
PollogenLumenis Be Ltd.Active, not recruitingModerate to Severe Acne VulgarisUnited States
-
Boston PharmaceuticalsCompletedModerate to Severe Acne VulgarisUnited States, Canada
-
Bispebjerg HospitalCompleted
Clinical Trials on SEB-250
-
Merete HaedersdalSebacia, Inc.CompletedAcne Vulgaris | MicroparticlesDenmark
-
Innovative Molecules GmbHCompleted
-
Lexicon PharmaceuticalsCompletedIrritable Bowel SyndromeUnited States
-
FytexiaCentros de Investigación de Nutrición y SaludRecruiting
-
Crossbow Therapeutics, Inc.RecruitingChronic Myeloid Leukemia | Chronic Myelomonocytic Leukemia (CMML) | High-risk Myelodysplastic Syndrome | AML - Acute Myeloid LeukemiaUnited States
-
Center for Research and Innovation Viña Concha...Universidad Católica del MauleNot yet recruitingInflammaging | Antioxidant Status, Inflammation | Inflammation Biomarkers | Antioxidant Capabilities | Cardiometabolic Health IndicatorsChile
-
Allievex CorporationEnrolling by invitationMPS III BUnited States, Germany, Turkey, United Kingdom, Colombia
-
Alaa EmaraRecruiting
-
BiocodexRecruitingIBS (Irritable Bowel Syndrome) | IBS, Mixed Symptoms | IBS-D (Diarrhea-predominant)Spain, Portugal
-
Toray Industries, IncCompletedIdiopathic Pulmonary FibrosisUnited States